Cancer Commons founder Dr. Marty Tenenbaum is featured in a new podcast from Mendelspod. In the podcast, entitled “4 Reasons Clinical Trials Don’t Work,” Dr. Tenenbaum outlines the shortcomings of the current state of the clinical trial system, and offer solutions for improvement. Cancer Commons is key to his vision of a revamped cancer research system that focuses on individual cancer patients to find answers faster. Listen on the website, or download the podcast to listen later.
Cancer Commons founder Dr. Marty Tenenbaum will be speaking tomorrow at the monthly meeting of Silicom Ventures, a Silicon Valley-based investment forum. Dr. Tenenbaum will discuss his vision for a personalized approach to oncology, offering solutions that could help answer these questions:
-Which are the best drugs and trials for me?
-How can I get timely and affordable access to the latest investigational drugs?
-How can we slash the time and cost of drug development so that the economics work for therapies that target small subsets of patients?
-Can cancer research be funded, one patient at a time?
The meeting takes place tomorrow, Sep. 10, in Santa Clara, CA. Guest registration is available on the event page.
In a recent video podcast, Cancer Commons board member Dr. Larry Marton discusses quality assurance in the context of personalized medicine. Dr. Marton is heavily involved at Cancer Commons; he tells our story at the 32:00 mark. From Mendelspod, makers of the podcast:
“Larry’s core message is that we must improve the quality of new clinical tests which have been translated from research. It is the key to demonstrating clinical relevance, he says. There are issues with sampling, with analytics, and with compliance. What can those in the industry do to better the quality assurance? And how can the industry better engage the medical community? A veteran shares his insights.”
You can also watch, listen, or download here.
Reporter Kerry Grens mentions Cancer Commons in a recent article in The Scientist. The piece explores the trend of self-tracking—monitoring one’s health over time using a variety of cutting-edge and traditional procedures, including genotyping, gut microbiome sequencing, hormone level measurement, heart rate variability tracking, weight measurement, and more. From the article:
“To further research, organizations have tapped into people’s interest in sharing personal data. Cancer Commons, a large network of cancer researchers, appeals to patients and their physicians to submit individual data on treatment, cancer genotype, and outcomes.”
Read the full article here.
Paul Howard writes about Cancer Commons in the new Forbes blog post “Can We Build a Kickstarter for Cancer?” From the post:
“The Cancer Commons approach – a distributed framework for empowering patients and learning from every patient/treatment combination – breaks down traditional distinctions between clinical trials and patient treatment in the “real world.” Instead of developing treatments in a lab and then testing them on randomized patients in clinical trials (designed to benefit future patients), researchers would apply the latest scientific knowledge and tools to help each patient achieve the best possible outcome today based on what we know – or think we can predict – about a molecular subtype of cancer.”
Read more here.
Cancer Commons is mentioned in a recently-published paper in The Journal of Oncopathology. In Crowdsourcing for Science and Medicine: Progress and Challenges, Sheryl Torr-Brown, PhD, writes:
“Another open source data collection effort to improve patient care is Cancer Commons, a nonprofit science initiative, comprised of an elite group of volunteer physicians and scientists, who collect patient data and make it broadly accessible for analysis. The initiative has already published a molecular disease model for lung cancer that is online and widely accessible.”
Read the paper here.
On June 10, the journal Nature Biotechnology published an article written by Cancer Commons founder Marty Tenenbaum. The piece addresses a previously published article that proposes a megafund approach to finance biomedical research. According to Dr. Tenenenbaum, the megafund approach will not only reduce risk for investors, but will also “slash the time, cost and risk of drug development by radically rethinking development processes, business models and organizational structures, and requiring the open sharing of data, knowledge and resources across portfolio projects. The resulting impact on productivity, risk and new therapeutic opportunities could potentially dwarf the returns from financial engineering.”
Read Dr. Tenenbaum’s article here: The Cancer Megafund: A Catalyst for Disruptive Innovation. Nature Biotechnology 31, 491-492 (2013) doi:10.1038/nbt.2605.
On May 7, Cancer Commons founder Marty Tenenbaum hosted a panel in The Scientist‘s three-part webinar series Decoding DNA: New Twists and Turns. A summary of the webinar was featured in the June issue of The Scientist: The Scientist June 2013 JMT Webinar. Watch Dr. Tenenbaum and other experts discuss The Impact of Personalized Medicine:
“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.
Jay M. (‘Marty’) Tenenbaum, Ph.D., Chairman and Founder, Cancer Commons
Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program
Geoffrey S. Ginsburg, MD, PhD, Director, Genomic Medicine, Duke Institute for Genome Sciences & Policy Executive Director, Center for Personalized Medicine Duke Medicine, Professor of Medicine and Pathology Duke University Medical Center
Abhijit ‘Ron’ Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson”
On Tuesday, May 7, Dr. Tenenbaum will host a panel in The Scientist‘s three-part webinar series Decoding DNA: New Twists and Turns. The series, which began on April 18, takes “a bold look at what the future holds for DNA research, bringing together senior investigators and key leaders in the field of genetics and genomics.” Dr. Tenenbaum will speak during the final webinar, The Impact of Personalized Medicine.
From The Scientist‘s description:
“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.”
Dr. Tenenbaum will be joined by Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program; and Abhijit “Ron” Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson.
When: Tuesday, May 7, 2013, 2:30–4:00 pm ET. Register here.